Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZURAGARD | — | 2021-06-24 | fda.gov ↗ |
| Approved | US (FDA) | CHLORAPREP ONE-STEP | — | 2000-07-14 | fda.gov ↗ |
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02990013 | Dec 2018 → Dec 2019 | toxic dermatosis | University of Miami | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04181463 | Nov 2026 → Dec 2028 expected | cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06836271 | Mar → Apr 2025 overdue | prostate cancer | Hitit University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03681990 | Jun → Jul 2017 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 2 | NCT02447497 | Mar → Apr 2015 | — | Solventum US LLC | Completed | No outcome recorded |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT04218110 | Feb → Mar 2020 | — | Professional Disposables International, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03782103 | Jan → May 2019 | — | Zurex Pharma, Inc. | Completed | Met primary |
| Phase 3 | NCT01361997 | Jun 2011 → Aug 2012 | infectious disease | University of Guanajuato | Completed | No outcome recorded |
| Phase 3 | NCT00799812 | Nov 2007 → Apr 2008 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 45 trials · 1 met primary | ||||||
| Phase 4 | NCT03489512 | Oct 2019 → Oct 2020 | infectious disease with sepsis | La Fe Health Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT03859908 | Apr 2019 → Jan 2021 | — | Universidad de El Salvador | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02760069 | Jan 2016 → Nov 2017 | — | Brooke Army Medical Center | Completed | Met primary |
| Phase 4 | NCT01366417 | May → Jun 2011 | — | C. R. Bard | Completed | No outcome recorded |
| Phase 4 | NCT01314703 | Mar → Apr 2011 | — | C. R. Bard | Completed | No outcome recorded |
| Phase not applicable4 trials · 1 missed | ||||||
| — | NCT04307550 | Jul 2021 → Oct 2024 | — | Anthony Seto | Completed | No outcome recorded |
| — | NCT02618343 | Oct 2016 → Mar 2019 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT02202577 | Mar 2014 → Jul 2016 | — | Case Western Reserve University | Completed | Missed primary |
| — | NCT01563406 | Mar 2012 → Jun 2013 | bacterial infectious disease | Rush University Medical Center | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 3 | NCT04756804 Background | Jun 2021 → Sep 2022 | — | Zurex Pharma, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05401292 Comparator | Feb 2022 → Dec 2026 expected | — | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT06733506 Comparator | Oct 2018 → May 2019 | substance-related disorder | Gabriel John Culbert | Completed | No outcome recorded |
| Phase 4 | NCT00739583 Comparator | Aug 2008 → Aug 2009 | osteoarthritis, hip | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT03656588 Comparator | Apr 2018 → Jan 2019 | bacterial infectious disease | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT02320695 Comparator | Mar 2015 | — | Johnson & Johnson Consumer and Personal Products Worldwide | Completed | No outcome recorded |
| — | NCT01233050 Comparator | Dec 2010 → Feb 2015 | — | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Isopropyl alcohol | “Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812 ↗24“Chloraprep® (chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583 ↗ “Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70% solution applied topically to intact skin” NCT03681990 ↗ “cutaneous asepsis with chlorhexidine gluconate at 2% + isopropyl alcohol 70%” NCT03489512 ↗ “Chlorhexidine gluconate 2% / Isopropyl alcohol 70%” NCT02447497 ↗ “Three large 2 ply 70% Isopropyl Alcohol swabs OR” NCT02618343 ↗ “Isopropyl alcohol (IPA) 70%” NCT03782103 ↗ |
| Known as | IPA | “Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)” NCT00739583 ↗3“Isopropyl alcohol (IPA), a topical skin disinfectant, is effective against many pathogens and is commonly supplied as 2x2 inch pre-soaked, single-use gauze wipes.” NCT06733506 ↗ “Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially” NCT00799812 ↗ “Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.” NCT02447497 ↗ |
| Modality | Other / unclassified | “70% isopropyl alcohol disinfection” PMID 42369177 ↗ Jun 2026 |
| Route | Topical | “Applied to skin pre-operatively for surgical site anti-sepsis” NCT02202577 ↗ |